Epitalon is a tetrapeptide isolate derived from epithalamin, which is a polypeptide extract originating from bovine pineal glands. Also known as epithalon, epitalon is produced naturally in small quantities, however, it is also available as a synthetic supplement that has been used in research settings. Some research indicates it may contribute to anti-aging via increasing the lifespans and longevity of mammalian cells (1).
Epitalon has been studied in the in vitro, in vivo, and in silicone settings, demonstrating its potential neuroprotective, antioxidant, and antimutagenic effects. These originate from several possible mechanisms of action, including:
Neuroprotection
When it comes to potential neuroprotective benefit, there are no studies in humans evaluating if epitalon prevents cognitive decline. However, preclinical research indicates it possesses antioxidant activity within the brain, and it can also increase melatonin levels.
Epithalon increased melatonin levels in older primates, however, it did not in rats. Additionally, epithalon treatment has been associated with lower levels of DNA damage and increased levels of phosphor-CREB, which is implicated in memory and learning. Thus, it may show promise in preventing cognitive decline.
Aging
There are a few Russian clinical studies that suggest a potential for epitalon to decrease mortality in older adults with cardiovascular disease. In a study of 70 older adults with cardiovascular disease, subjects received epithalamin treatment every six months for three years. Individuals were followed for an additional nine years thereafter. Through the course of the 12 years, those treated with epithalamin demonstrated a 28% decreased mortality rate. Additionally, there was a two-fold decreased rate of mortality associated with cardiovascular disease.
Both epithalamin and epithalon treatment have been shown to increase lifespan in rats, mice, and flies. It is important to note, however, that these results have not been replicated outside of one particular investigator’s lab (3).
There are a few Russian clinical studies that suggest a cardiovascular and decreased mortality benefit, indicating potential efficacy in aging and related health concerns. While preclinical studies also demonstrate a neuroprotective advantage associated with epitalon treatment, these findings have not been confirmed in humans.
Epitalon is currently nominated as a Category 2 Bulk Substance under 503A as of September 2023. This means that there are safety risks identified by the US Food and Drug Administration (FDA), including immunogenicity.
The FDA plans to consult an advisory committee in July 2026 regarding inclusion of epitalon bulk substances on the 503A bulk list (4,5).
The two treatment trials in Russia did not report any serious adverse events associated with epitalon. Additionally, preclinical studies have not flagged any potential safety concerns. However, a well-controlled Phase 1 study is needed to fully characterize the safety profile of epitalon.
Preliminary clinical evidence of epitalon in humans suggests a potential anti-aging effect, while preclinical evidence also supports its use in promoting cognition. Epitalon could be an option for individual seeking these beneficial effects, as long as it is used with caution given the unknown safety profile and limited clinical evidence.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
References
